News Briefs: 23andMe’s Mea Culpa; FDA Reaches Settlement With J&J; Meaningful Use Delay
This article was originally published in The Gray Sheet
Executive Summary
Genetic testing firm 23andMe has stopped providing its genetic tests to consumers, following a warning letter from FDA. The agency has reached a $1.25 million settlement with Johnson & Johnson’s Advanced Sterilization Products group. HHS agencies announced delay in health IT meaningful use implementation. More news.
You may also be interested in...
Active Months Ahead For mHealth Regulatory Policymaking
Multiple guidances, frameworks and legislative activity on mHealth are expected to surface this fall and could have major implications on how the emerging industry is regulated.
Active Months Ahead For mHealth Regulatory Policymaking
Multiple guidances, frameworks and legislative activity on mHealth are expected to surface this fall and could have major implications on how the emerging industry is regulated.
Lawmakers Want HIPAA Data Access Rules Amended To Encourage Consumer ‘Shopping’ For Diagnostics
Lawmakers at a House hearing discussed amending the HIPAA privacy regulations to allow patients more access to their own data, and to encourage patient participation in selecting their own genetic tests, mammograms or other diagnostics.